Malignant Neoplasm of Transverse ColonPhase 2NCT01861691
Randomized Controlled Trial Between Laparoscopic and Open Surgery in Transverse and Descending Colon Cancer Patients
A Phase 2 study testing Open surgery and Laparoscopic surgery in people with Malignant Neoplasm of Transverse Colon and Malignant Neoplasm of Descending Colon, run by Shoichi Fujii, MD, PhD at 1 site in Japan.
Trial summary
The long-term results of several large-scale prospective randomized trials that compared laparoscopic-assisted and open colectomy for colon cancer were published in the past decade. The oncologic outcomes were nearly similar in patients who underwent laparoscopic or open surgery. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Malignant Neoplasm of Transverse Colon, Malignant Neoplasm of Descending Colon
- What is being tested?
- Open surgery and Laparoscopic surgery
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 66 participants
- Where
- 1 siteJapan
- Study dates
- Aug 2008to Oct 2017
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age of 20 years old or over
- Histologically proven adenocarcinoma
- Clinical tumor penetrates visceral peritoneum (T4a), no metastasis (M0) or lower T factor
- Elective operation
- Tolerable surgery under general anesthesia
- No bulky tumor larger than 8cm in diameter
- No history of laparotomy for colorectal resection except appendectomy
- Provided written informed consent
Who cannot join
- Synchronous or metachronous (within 5 years) malignancy in another organ except carcinoma in situ
- Multiple colorectal cancer that needs reconstruction two or more times
- Acute intestinal obstruction or perforation due to colorectal cancer
- Lower rectal cancer that required pelvic side wall lymphadenectomy
- Pregnant or lactating women
Trial locations and contacts
1 site in 1 country.
Japan1 site
Yokohama City University Medical Center
Yokohama, Kanagawa, 232-0024
About this study
Official title: Randomized Controlled Trial to Evaluate Laparoscopic Versus Open Surgery in Transverse and Descending Colon Cancer Patients
The long-term results of several large-scale prospective randomized trials that compared laparoscopic-assisted and open colectomy for colon cancer were published in the past decade. The oncologic outcomes were nearly similar in patients who underwent laparoscopic or open surgery. In Japan, the Japan Clinical Oncology Group (JCOG) conducted a randomized trial to compare oncological outcomes between patients who underwent laparoscopic or open surgery for advanced colon cancer and recto-sigmoid cancer. However, the exclusion criterion were concerning tumor site in transverse and descending colon. The reason of exclusion was that laparoscopic procedure was difficult in transverse and descending colon cancers. However, laparoscopic surgery for transverse and descending colon cancer was performed clinically. We conducted a randomized trial that compared laparoscopic surgery and conventional open surgery in in transverse and descending colon cancer. The purpose of the present study was to clarify the safety and feasibility of laparoscopic surgery on in transverse and descending colon cancer patients.
Read the detailed description
Patients
- This was a randomized controlled trial conducted at a single institute, which was Yokohama City University Medical Center (Japan).
- 80 patients who had transverse colon or descending colon cancer were randomly allocated to receive laparoscopic surgery or conventional open surgery.
Surgical procedures
- All surgical procedures were performed by one specialized colorectal treatment team. The laparoscopic surgeries were performed by a surgeon who passed the skill accreditation system for laparoscopic gastroenterological surgery was established by the Japanese Society for Endoscopic Surgery (JSES), and all open surgeries were performed under the supervision of these skillful surgeons.
- All operations were performed according to the standard radical cure procedure described in the seventh edition of the Japanese General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. That is, intestinal excision with lymph node dissection that separated the feeding blood vessel at its origin was performed in all surgical procedures. Patients who underwent palliative partial excision were not included.
- In the laparoscopic surgery, a medial-to-lateral approach was performed in all patients.
- In the conventional open surgery, the first procedure was done in lateral approach. The reconstruction techniques were the same as those used in laparoscopic surgery.
Randomization - To balance the operative backgrounds between the laparoscopic and the conventional open surgery groups, the patients were stratified by the tumor location (transverse colon, descending colon).
Adjuvant therapy
- When the pathological stage was diagnosed as stage 3 by histological examination of the resected specimen, adjuvant chemotherapy was done with oral fluoropyrimidine anti-cancer drug.
- Neither radiation therapy nor preoperative chemotherapy was given to any patient. Preoperative chemo-radiotherapy even for rectal cancer is not yet standard treatment in Japan.
Assessment parameters
- The preoperative parameters
- Operative assessment parameters
- Postoperative assessment parameters An early postoperative complication was defined as a complication that occurred between the finish of the operation and postoperative day 30. A late postoperative complication was defined as a complication that occurred after postoperative day 30. The terminologies of complications were classified according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, and grading was done by Classification of Surgical Complication.
- The pathological results were recorded according to the 7th edition of the Japanese General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus and 7th edition of primary tumor, regional nodes, metastasis (TNM) classification. Circumferential margin involvement was defined as exposure of a cancer cell at the vertical dissection surface on histological examination.
- Quality of life (QOL) scores. The QOL score was measured using the 36-item Short Form Health Survey (SF-36) version 2.0. It is a tool that measures health-related QOL (HRQOL) according to an inclusive standard and not a disease-specific standard. The SF-36 is composed of 36 questions. The score is expressed numerically by the provided scoring algorithm. SF-36 questionnaires were sent to the patients at one month, 6 months and one year after the surgery by postal mail. A return envelope was enclosed with the SF-36 questionnaire, and the patient sent it back to the research secretariat by postal mail. A questionnaire on the defecation situation and wound pain besides the SF-36 was added all three times. The question of when complete rehabilitation occurred was added in the questionnaire at one year.
Follow-up schedule
- The follow-up schedule was as follows according to stage. Patients with stages 0 and I were followed up with outpatient examinations including tumor marker measurements, and chest, abdominal and pelvic computed tomography (CT) once a year for five years. Patients with stage 2 and 3a were examined by CT and tumor marker measurements every six months for the first two years. These examinations were done once a year from the third year to the fifth year. Patients with stage 3b and 3c were examined by CT and tumor marker measurements every four months for the first two years, and every six months from the third year to the fifth year.
Statistical analysis
- The primary endpoint was early complication rate.
- The secondary endpoints were 5-recurrence-free survival, 5-year overall survival, length of postoperative hospital stay, and HRQOL score. To evaluate whether a difference in the operative procedure influences survival including death due to another disease, a comparison of overall survival has meaning. Early complication rate, length of postoperative hospital stay and HRQOL score were added to the secondary endpoints because these parameters had a possibility of becoming grounds of selection of the operation method if there were no differences in overall survival and recurrence-free survival.
- A sample size of 74 patients was assured to achieve a power of more than 70% to detect a difference between the groups using a two-sided Chi-squared test with type I error rate equal to 0.2, when the true complication rates were 20% and 40% for the laparoscopic and open surgeries, respectively. The dropouts were considered and the number of accumulation targets was assumed to be 80 patients.
- For continuous variables, data are presented as means ± standard deviation (SD). For categorical variables, data are presented as frequencies and percentages (%). Comparison of the endpoints was based on intention-to-treat principle, that is, the patients who switched to another group during surgery were treated as members of the allocated group. The Chi-squared test was applied to evaluate the significance of differences in proportions, and t-test was used to evaluate the significance of differences in continuous variables. A p-value of less than 0.05 was considered to be statistically significant.
- Being tested
- Open surgery, Laparoscopic surgery
- Keywords
- Transverse colon cancer, Descending colon cancer, Laparoscopic surgery, Randomized controlled trial
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Open surgeryProcedure or surgery
Also called Open colectomy
Conventional technique
Laparoscopic surgeryProcedure or surgery
Also called Laparoscopic colectomy
New minimum invasive technique
| Study group | Role | What they receive |
|---|---|---|
| Open surgery | Active comparator | Open colectomy Receives: Procedure: Open surgery |
| Laparoscopic surgery | Experimental | Laparoscopic colectomy Receives: Procedure: Laparoscopic surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Early complication rate
Early complication is defined as a complication that occured between the finish of the surgery and postoperative day 30.
Measured: within the first 30 days after surgery
Secondary outcomes (4)
Recurrence-free survival
All death and recurrence of colon cancer is defined as an event of recurrence-free survival.
Measured: 5 years
Overall survival
All death is defined as an event of overall survival.
Measured: 5 years
Length of postoperative hospital stay
Length of postoperative hospital stay is defined as a duration between surgery and first discharge. An expected average is 10 days.
Measured: 10 days
Health-related QOL score
The QOL score was measured using the 36-item Short Form Health Survey (SF-36) version 2.0. It is a tool that measures health-related QOL (HRQOL) according to an inclusive standard and not a disease-specific standard. The SF-36 is composed of 36 questions. The score is expressed numerically by the provided scoring algorithm. SF-36 questionnaires were sent to the patients at one month, 6 months and one year after the surgery by postal mail. A return envelope was enclosed with the SF-36 questionnaire, and the patient sent it back to the research secretariat by postal mail. A questionnaire on the defecation situation and wound pain besides the SF-36 was added all three times. The question of when complete rehabilitation occurred was added in the questionnaire at one year.
Measured: 1 year after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 May 2013 (estimated)
- Study startAug 2008
- Primary completionOct 2012
- Study completionOct 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Malignant Neoplasm of Transverse ColonStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 66 participants (actual)
Sponsor and investigators
- Lead sponsor
- Shoichi Fujii, MD, PhD
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Shoichi Fujii, MD, PhD, Yokohama City University Medical Center
- Investigators
- Chikara Kunisaki, Professor, Study chair, Yokohama City University, Gastroenterological Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01861691
- Sponsor's protocol ID
- YCUMC-D1108014
- Other IDs
- YokohamaCUMC33
- Status last verified
- Nov 2013
- First submitted
- 21 May 2013
- Last updated
- 26 Nov 2013
- Results posted
- No
- Data monitoring committee
- No
Publications
Toritani K, Watanabe J, Nakagawa K, Suwa Y, Suwa H, Ishibe A, Ota M, Fujii S, Kunisaki C, Endo I. Randomized controlled trial to evaluate laparoscopic versus open surgery in transverse and descending colon cancer patients. Int J Colorectal Dis. 2019 Jul;34(7):1211-1220. doi: 10.1007/s00384-019-03305-2. Epub 2019 May 17.
PubMed 31102008
Study at a glance
From the registry record, last updated by the sponsor on 26 Nov 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Controlled Trial to Evaluate Laparoscopic Versus Open Surgery in Transverse and Descending Colon Cancer Patients
- ClinicalTrials.gov ID
- NCT01861691
- Acronym / sponsor ID
- YCUMC-D1108014
- Keywords
- Transverse colon cancer, Descending colon cancer, Laparoscopic surgery, Randomized controlled trial
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 66 participants (actual)
- Lead sponsor
- Shoichi Fujii, MD, PhDUniversity, hospital or other
- Study start
- Aug 2008
- Primary completion
- Oct 2012 (actual)
- Study completion
- Oct 2017 (estimated)
- First posted
- 23 May 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The long-term results of several large-scale prospective randomized trials that compared laparoscopic-assisted and open colectomy for colon cancer were published in the past decade. The oncologic outcomes were nearly similar in patients who underwent laparoscopic or open surgery. In Japan, the Japan Clinical Oncology Group (JCOG) conducted a randomized trial to compare oncological outcomes between patients who underwent laparoscopic or open surgery for advanced colon cancer and recto-sigmoid cancer. However, the exclusion criterion were concerning tumor site in transverse and descending colon. The reason of exclusion was that laparoscopic procedure was difficult in transverse and descending colon cancers. However, laparoscopic surgery for transverse and descending colon cancer was performed clinically. We conducted a randomized trial that compared laparoscopic surgery and conventional open surgery in in transverse and descending colon cancer. The purpose of the present study was to clarify the safety and feasibility of laparoscopic surgery on in transverse and descending colon cancer patients.
Detailed description
Patients
- This was a randomized controlled trial conducted at a single institute, which was Yokohama City University Medical Center (Japan).
- 80 patients who had transverse colon or descending colon cancer were randomly allocated to receive laparoscopic surgery or conventional open surgery.
Surgical procedures
- All surgical procedures were performed by one specialized colorectal treatment team. The laparoscopic surgeries were performed by a surgeon who passed the skill accreditation system for laparoscopic gastroenterological surgery was established by the Japanese Society for Endoscopic Surgery (JSES), and all open surgeries were performed under the supervision of these skillful surgeons.
- All operations were performed according to the standard radical cure procedure described in the seventh edition of the Japanese General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. That is, intestinal excision with lymph node dissection that separated the feeding blood vessel at its origin was performed in all surgical procedures. Patients who underwent palliative partial excision were not included.
- In the laparoscopic surgery, a medial-to-lateral approach was performed in all patients.
- In the conventional open surgery, the first procedure was done in lateral approach. The reconstruction techniques were the same as those used in laparoscopic surgery.
Randomization - To balance the operative backgrounds between the laparoscopic and the conventional open surgery groups, the patients were stratified by the tumor location (transverse colon, descending colon).
Adjuvant therapy
- When the pathological stage was diagnosed as stage 3 by histological examination of the resected specimen, adjuvant chemotherapy was done with oral fluoropyrimidine anti-cancer drug.
- Neither radiation therapy nor preoperative chemotherapy was given to any patient. Preoperative chemo-radiotherapy even for rectal cancer is not yet standard treatment in Japan.
Assessment parameters
- The preoperative parameters
- Operative assessment parameters
- Postoperative assessment parameters An early postoperative complication was defined as a complication that occurred between the finish of the operation and postoperative day 30. A late postoperative complication was defined as a complication that occurred after postoperative day 30. The terminologies of complications were classified according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, and grading was done by Classification of Surgical Complication.
- The pathological results were recorded according to the 7th edition of the Japanese General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus and 7th edition of primary tumor, regional nodes, metastasis (TNM) classification. Circumferential margin involvement was defined as exposure of a cancer cell at the vertical dissection surface on histological examination.
- Quality of life (QOL) scores. The QOL score was measured using the 36-item Short Form Health Survey (SF-36) version 2.0. It is a tool that measures health-related QOL (HRQOL) according to an inclusive standard and not a disease-specific standard. The SF-36 is composed of 36 questions. The score is expressed numerically by the provided scoring algorithm. SF-36 questionnaires were sent to the patients at one month, 6 months and one year after the surgery by postal mail. A return envelope was enclosed with the SF-36 questionnaire, and the patient sent it back to the research secretariat by postal mail. A questionnaire on the defecation situation and wound pain besides the SF-36 was added all three times. The question of when complete rehabilitation occurred was added in the questionnaire at one year.
Follow-up schedule
- The follow-up schedule was as follows according to stage. Patients with stages 0 and I were followed up with outpatient examinations including tumor marker measurements, and chest, abdominal and pelvic computed tomography (CT) once a year for five years. Patients with stage 2 and 3a were examined by CT and tumor marker measurements every six months for the first two years. These examinations were done once a year from the third year to the fifth year. Patients with stage 3b and 3c were examined by CT and tumor marker measurements every four months for the first two years, and every six months from the third year to the fifth year.
Statistical analysis
- The primary endpoint was early complication rate.
- The secondary endpoints were 5-recurrence-free survival, 5-year overall survival, length of postoperative hospital stay, and HRQOL score. To evaluate whether a difference in the operative procedure influences survival including death due to another disease, a comparison of overall survival has meaning. Early complication rate, length of postoperative hospital stay and HRQOL score were added to the secondary endpoints because these parameters had a possibility of becoming grounds of selection of the operation method if there were no differences in overall survival and recurrence-free survival.
- A sample size of 74 patients was assured to achieve a power of more than 70% to detect a difference between the groups using a two-sided Chi-squared test with type I error rate equal to 0.2, when the true complication rates were 20% and 40% for the laparoscopic and open surgeries, respectively. The dropouts were considered and the number of accumulation targets was assumed to be 80 patients.
- For continuous variables, data are presented as means ± standard deviation (SD). For categorical variables, data are presented as frequencies and percentages (%). Comparison of the endpoints was based on intention-to-treat principle, that is, the patients who switched to another group during surgery were treated as members of the allocated group. The Chi-squared test was applied to evaluate the significance of differences in proportions, and t-test was used to evaluate the significance of differences in continuous variables. A p-value of less than 0.05 was considered to be statistically significant.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Open surgery | Active comparator | Procedure: Open surgeryOpen colectomy |
| Laparoscopic surgery | Experimental | Procedure: Laparoscopic surgeryLaparoscopic colectomy |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Age of 20 years old or over
- Histologically proven adenocarcinoma
- Clinical tumor penetrates visceral peritoneum (T4a), no metastasis (M0) or lower T factor
- Elective operation
- Tolerable surgery under general anesthesia
Key exclusion criteria (5 listed)
- Synchronous or metachronous (within 5 years) malignancy in another organ except carcinoma in situ
- Multiple colorectal cancer that needs reconstruction two or more times
- Acute intestinal obstruction or perforation due to colorectal cancer
- Lower rectal cancer that required pelvic side wall lymphadenectomy
- Pregnant or lactating women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Open surgeryAlso: Open colectomyConventional technique | Procedure or surgery | Open surgery |
| Laparoscopic surgeryAlso: Laparoscopic colectomyNew minimum invasive technique | Procedure or surgery | Laparoscopic surgery |
Primary outcome
Early complication rate
Time frame: within the first 30 days after surgery
Early complication is defined as a complication that occured between the finish of the surgery and postoperative day 30.
4 secondary outcomes
Recurrence-free survival
Time frame: 5 years
Overall survival
Time frame: 5 years
Length of postoperative hospital stay
Time frame: 10 days
Health-related QOL score
Time frame: 1 year after surgery
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Nov 2013.
- Derived from this study: PubMed 31102008Toritani K, Watanabe J, Nakagawa K, Suwa Y, Suwa H, Ishibe A, Ota M, Fujii S, Kunisaki C, Endo I. Randomized controlled trial to evaluate laparoscopic versus open surgery in transverse and descending colon cancer patients. Int J Colorectal Dis. 2019 Jul;34(7):1211-1220. doi: 10.1007/s00384-019-03305-2. Epub 2019 May 17.
Related trials for Malignant Neoplasm of Transverse Colon
Recruiting
LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer
Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer
Recruiting
LIRRH Trial for the Right-sided Colon Cancer
Ascending Colon Cancer, Proximal Transverse Colon Cancer
Recruiting
Postoperative Effects of Different Enterostomy Approaches
Colorectal Cancer, Colorectal Neoplasms Malignant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chikara Kunisaki, Professor study chair
Yokohama City University, Gastroenterological Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Open surgery and Laparoscopic surgery in people with Malignant Neoplasm of Transverse Colon and Malignant Neoplasm of Descending Colon, run by Shoichi Fujii, MD, PhD at 1 site in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Nov 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Early complication rate (time frame: within the first 30 days after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01861691, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2013.